UW-CTRI logo
Researchers > Understanding Tobacco Dependence and Its Treatment
UW-CTRI News Click here for more on the Wisconsin Tobacco Quit Line To acess UW-CTRI publications, click here For more about UW-CTRI programs, click here

Click here for the HealthCare Providers Page
Click here for information to help smokers quit
Click here for information on smoking for insurers
Click here for information for employers to help employees quit
Click here for information for policymakers and tobacco control advocates
Click here for the UW-CTRI home page

Clinical Trials: New Medication

Because of an increased national interest in new medications to treat tobacco dependence, UW-CTRI has recently conducted clinical trials for new medications.

Selegiline
UW-CTRI is testing a new stop-smoking medicine, selegiline, in the form of a patch. For more information, click here.

Nicotine Vaccine
UW-CTRI is currently testing the efficacy of this vaccine, designed to attach to nicotine molecules in tobacco products and prevent their absorption by the brain.

Varenicline
This new prescription medication, marketed as "Chantix," was approved by the FDA to help patients quit smoking. Varenicline acts on nicotine receptors with two types of action: 

  1. It blocks some of the rewarding effects of nicotine.
  2. At the same time, it stimulates the receptors in a way that reduces withdrawal. 

UW-CTRI is currently one of several research sites across the world testing the safety of this medication for patients with cardiovascular diagnoses. For more information on varenicline, click here.


© 2007 UW-CTRI